-
Abstract Number: 1035
Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors
-
Abstract Number: 1036
A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care
-
Abstract Number: 1037
Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
-
Abstract Number: 1038
IMPACT (Impact of eMbedded Pharmacists in an Academic Center sTudy)
-
Abstract Number: 1039
Through the LuCIN Lens: Defining Barriers and Forging Solutions for Lupus Clinical Trials in North America
-
Abstract Number: 1040
Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics
-
Abstract Number: 1041
A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis
-
Abstract Number: 1042
Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
-
Abstract Number: 1043
A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3)
-
Abstract Number: 1044
Analysis of Rheumatic Patients’ Self – Reported Symptoms in Free Written Text Using Natural Language Processing
-
Abstract Number: 1045
Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
-
Abstract Number: 1046
Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology
-
Abstract Number: 1047
Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
-
Abstract Number: 1048
Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus
-
Abstract Number: 1049
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
- « Previous Page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- …
- 181
- Next Page »